ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals (NASDAQ:SPRY) held its Q1 2026 earnings call, reporting $22.7 million in total revenue, with $17.5 million from U.S. neffy net product revenue, triple the volume year-over-year. Despite missing EPS expectations, the company highlighted strong commercial momentum for neffy, focusing on expanding access, improving affordability for patients, increasing prescriber adoption, and strengthening consumer awareness. Key initiatives include nearing approval for broader CVS Caremark coverage, introducing a $199 cash price option at retail pharmacies, expanding the sales force, and securing Medicaid coverage in additional states, with expectations for significant growth in the second half of 2026.
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, with neffy® (epinephrine nasal spray) U.S. net product revenue at $17.5 million. The company is advancing neffy's commercialization, including final stages of CVS Caremark approval and expanded state Medicaid coverage, and has completed a sales force expansion. ARS Pharma also announced Health Canada approval for neffy and European Commission marketing authorization for EUR neffy® 1 mg, alongside progress in its Phase 2b CSU trial.
ARS Pharmaceuticals (SPRY) Losses Challenge Bullish Neffy Growth Story In Q1 2026
ARS Pharmaceuticals (SPRY) reported Q1 2026 revenue of US$84.3 million but a significant loss of US$171.3 million, challenging the bullish outlook for its Neffy product. Despite projected strong revenue and earnings growth towards profitability by 2029, current losses raise concerns about execution risk and the company's ability to offset high operating costs. Analysts' optimistic price targets require a substantial shift in profitability, far from the current financial situation.
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals reported strong Q1 2026 results with $22.7 million in revenue, driven by increased adoption of its needle-free epinephrine treatment, Neffy. The company is prioritizing access, affordability, and adoption, focusing on reducing prior authorization requirements and ensuring a maximum cash price of $199 for patients. ARS expects to reach cash flow breakeven by mid-2027 and is expanding its commercial efforts and international presence for Neffy.
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals reported its financial results and provided a corporate update for the first quarter of 2026. The report includes key financial data, operational achievements, and future outlook for the company. This press release outlines the company's performance during the quarter and important developments.
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter results showing a revenue beat but an earnings miss, causing its shares to rise 2.39% in pre-market trading. The company's total revenue reached $22.7 million, exceeding estimates, driven by sales of its needle-free epinephrine nasal spray, neffy. Despite an increase in Net Loss and SG&A expenses, ARS Pharma management believes their current cash reserves are sufficient to fund operations to cash-flow break-even.
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals reported first-quarter 2026 financial results with total revenue of $22.7 million, driven by neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million. The company is advancing neffy's commercialization, including progress with CVS Caremark for formulary approval and expansion into state Medicaid plans, while also pursuing global approvals and clinical development in chronic spontaneous urticaria. ARS Pharma expanded its sales force and received FDA approval to remove age criteria for 1 mg neffy, further broadening its market reach.
ARS Pharmaceuticals (NASDAQ: SPRY) grows neffy sales but posts $60.6M Q1 loss
ARS Pharmaceuticals reported strong Q1 2026 revenue of $22.7 million, tripling the previous year, primarily driven by $17.5 million in U.S. net product sales of neffy. Despite this growth, the company posted a net loss of $60.6 million due to significant investments in commercialization, including expanding its sales force and direct-to-consumer marketing. ARS Pharma maintains a solid cash position of $201.0 million, expecting it to fund operations through cash-flow break-even, while continuing to advance neffy's market penetration and a Phase 2b trial for chronic spontaneous urticaria.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) reported a Q1 loss of $0.61 per share, missing the Zacks Consensus Estimate of a $0.53 loss, but exceeded revenue estimates with $22.68 million against an expected $22.23 million. Despite beating revenue expectations for the fourth consecutive quarter, the company's stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank is a #4 (Sell) due to unfavorable estimate revisions. The earnings outlook for the medical-drugs industry, to which ARS Pharmaceuticals belongs, is also considered a factor in its stock performance.
ARS Pharmaceuticals Appoints Donn Casale as New President
ARS Pharmaceuticals has appointed Donn Casale as its new President, effective June 1, 2026. Casale brings over 25 years of biopharmaceutical experience and will receive a base salary of $575,000, a discretionary bonus, and a $6 million stock option award. While ARS Pharmaceuticals has a "Buy" rating from analysts, TipRanks' AI Analyst, Spark, rates SPRY as "Neutral" due to weak financial performance and limited positive momentum, despite strong gross margins and a debt-free balance sheet.
ARS Pharmaceuticals appoints Donn Casale as president
ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as President, effective June 1, 2026, where he will oversee global commercial operations and growth infrastructure. Casale previously served as Chief Commercial Officer at Dynavax Technologies, significantly growing their hepatitis B vaccine, HEPLISAV-B. This appointment comes as ARS Pharmaceuticals prepares for expansion and continues to market neffy, an epinephrine nasal spray for severe allergic reactions.
ARS Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
ARS Pharmaceuticals Inc (SPRY) is anticipated to report a loss of 53 cents per share. This information comes from a Refinitiv earnings preview. The full article provides limited details beyond this financial projection.
Donn Casale to become President of ARS Pharmaceuticals (SPRY) with $6M option grant
ARS Pharmaceuticals (SPRY) announced the appointment of Donn Casale as its new President, effective June 1, 2026. He will receive an annual base salary of $575,000, a 45% discretionary bonus target, and a stock option valued at $6,000,000. Current President and CEO Richard Lowenthal will continue as Chief Executive Officer.
Needle-free allergy spray maker ARS Pharma brings in new president
ARS Pharmaceuticals (Nasdaq: SPRY) has appointed Donn Casale as President, effective June 1, 2026, while Richard Lowenthal remains CEO. Casale will lead global commercial operations for neffy (epinephrine nasal spray) and support the company's expansion into chronic spontaneous urticaria. He brings 25 years of biopharmaceutical commercial leadership experience, including scaling HEPLISAV-B to over $300 million in annualized revenue at Dynavax.
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
ARS Pharmaceuticals has appointed Donn Casale as its new President, effective June 1, 2026. Casale, an industry veteran with 25 years of experience, will lead global commercial operations and growth infrastructure, focusing on accelerating the adoption and sales growth of neffy® (epinephrine nasal spray) and expanding into chronic spontaneous urticaria (CSU). Richard Lowenthal will continue as CEO, working with Casale to drive the company's next phase of commercial and organizational growth.
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. The company, known for commercializing neffy® (epinephrine nasal spray) for severe allergic reactions, has provided details for accessing the event and a replay.
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. The biopharmaceutical company focuses on empowering at-risk patients with solutions for anaphylaxis, including its neffy® epinephrine nasal spray. A replay of the webcast will be available for 30 days.
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) will host a conference call and webcast on Friday, May 15, 2026, to discuss its first quarter 2026 financial results and business highlights. The event will take place at 5:30 a.m. PT / 8:30 a.m. ET, with dial-in and webcast access details provided for interested participants. The company specializes in developing treatments for allergic reactions, including an epinephrine nasal spray called neffy®.
ARS Pharma will discuss Q1 results May 15 in investor webcast
ARS Pharmaceuticals (Nasdaq: SPRY) announced it will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights. Investors will need to register for the event to obtain dial-in details, and a webcast replay will be available for 30 days. The announcement also notes historical stock movements for similar notices have been modest.
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced it will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET. The event will cover the company's first quarter 2026 financial results and business highlights. ARS Pharma specializes in therapies for allergic reactions, including its neffy® epinephrine nasal spray.
ARS Pharmaceuticals (Nasdaq:SPRY) - Stock Analysis
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company focused on developing treatments for severe allergic reactions, primarily with its needle-free epinephrine nasal spray, Neffy. The company is trading significantly below its fair value estimate, with strong projected earnings growth of 63.49% annually. Recent achievements include regulatory approvals for Neffy in Canada and China, and the removal of age criteria for Neffy 1 mg in the U.S., expanding its market potential.
Earnings preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 earnings expected to decline
This article provides an earnings preview for ARS Pharmaceuticals, Inc. (SPRY) for Q1, anticipating a decline in earnings per share compared to the previous year. It suggests that the company's financial performance may indicate challenges or shifts in its operations.
ARS Pharmaceuticals (NASDAQ: SPRY) sets 2026 meeting, highlights neffy launch and cash runway
ARS Pharmaceuticals (NASDAQ: SPRY) has announced its 2026 annual meeting for June 24, 2026, where stockholders will vote on directors, auditor ratification, and executive compensation. The company highlighted the successful first full year of commercializing its neffy epinephrine nasal spray, with widespread adoption and over 90% commercial coverage in the U.S., alongside international approvals. ARS also reported $245 million in cash, cash equivalents, and short-term investments at the end of 2025, which it expects to fund operations through cash-flow breakeven, and is progressing a Phase 2b trial for intranasal epinephrine in chronic spontaneous urticaria.
[ARS] ARS Pharmaceuticals, Inc. SEC Filing
This article announces an SEC filing by ARS Pharmaceuticals, Inc. (SPRY) of type ARS, filed on April 29, 2026, at 4:05 PM. The filing's sentiment is neutral and its impact is low. The document is available as a PDF and can be viewed on SEC EDGAR, providing essential information for investors tracking SPRY's regulatory disclosures.
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock?
This article reports that ARS Pharmaceuticals, Inc. (SPRY) experienced a 7.1% increase in its stock price, raising the question of whether further upside potential exists. Without additional content, it's impossible to determine the reasons for this surge or future outlook.
BlackRock (SPRY) files amendment showing 4.98% ownership
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing beneficial ownership of 4,946,412 shares of ARS Pharmaceuticals, Inc. common stock, which represents 4.98% of the class. The filing indicates BlackRock holds sole voting power for 4,860,113 shares and sole dispositive power for all 4,946,412 shares. This amendment, signed by Spencer Fleming, Managing Director, on April 27, 2026, confirms that BlackRock's ownership is less than 5% and is held for passive investment purposes.
Avoiding Lag: Real-Time Signals in (SPRY) Movement
Quantitative Research Desk analyzes Ars Pharmaceuticals Inc. (NASDAQ: SPRY), noting positive near-term sentiment with a broader weak alignment. The report highlights a mid-channel oscillation pattern and an exceptional 126.0:1 risk-reward setup targeting a 32.8% gain versus 0.3% risk. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and AI-generated signals for SPRY.
ARS Pharmaceuticals Q3 2025 Earnings Preview
This article is a Q3 2025 earnings preview for ARS Pharmaceuticals. It serves as an announcement for upcoming financial results without providing specific details in the current content. The full article content is an empty placeholder, indicating no actual preview information is available yet.
FDA Approves Neffy Needle-Free Epinephrine Nasal Spray for Younger Children
The FDA has approved Neffy 1 mg (epinephrine nasal spray) for children aged 4 and older weighing 15 to under 30 kg, offering the first needle-free treatment for severe allergic reactions in this pediatric population in over 35 years. This approval addresses the significant caregiver fear associated with needle-based auto-injectors, which often leads to delayed, life-saving treatment. Clinical trials confirmed bioequivalence to traditional injections, and the device is designed for easy, reliable use by both children and untrained individuals.
FDA Approves Expanded Use for ARS Pharmaceuticals Nasal Spray
The FDA has approved an expanded use for ARS Pharmaceuticals' needle-free epinephrine nasal spray, neffy 1 mg, eliminating prior age restrictions for emergency treatment of severe allergic reactions. The updated guidance allows use for patients weighing at least 33 pounds and provides new storage and handling instructions. Northland initiated coverage with an outperform rating and a $25 price target, viewing the nasal spray as a significant innovation.
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions
Health Canada has approved neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions in adults and children weighing 30 kg or more, making it the first needle-free epinephrine treatment available in Canada. This approval, following a similar clearance in China, is a significant advancement for patients at risk of anaphylaxis, offering a convenient and timely treatment option. ARS Pharmaceuticals, developer of neffy, expects the product to be available in Canada in summer 2026 through its licensing agreement with ALK-Abelló A/S.
Canada clears first needle-free epinephrine for severe allergies
ARS Pharmaceuticals (Nasdaq: SPRY) has announced that Health Canada has approved neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions in adults and children weighing 30 kg or more. This marks the first needle-free epinephrine option for Canada, with availability expected in summer 2026 through a partnership with ALK Canada. ARS Pharma has received $155 million in upfront and milestone payments and is eligible for additional payments and royalties.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), with an average one-year price target of $28.25. The company's shares recently traded at $8.14, reflecting a market capitalization of $808 million, and it reported EPS of -$0.42, which met estimates, alongside revenues surpassing expectations. Institutional investors have notably increased their holdings in the company.
Northland initiates ARS Pharmaceuticals stock with outperform rating
Northland initiated coverage on ARS Pharmaceuticals Inc (NASDAQ:SPRY) with an Outperform rating and a $25.00 price target, highlighting the potential of its neffy product, a needle-free intranasal epinephrine treatment. The firm anticipates neffy will achieve U.S. peak sales exceeding $1 billion due to expected improvements in market access and adoption from new and existing users. This positive outlook follows ARS Pharmaceuticals' strong Q4 2025 earnings and a recent FDA label update removing an age restriction for neffy.
SPRY Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of ARS Pharmaceuticals Inc (SPRY), detailing its revenue breakdown, profitability margins, and a comparison with competitors. SPRY maintains a gross margin of 78.09% but reports negative operating and net margins, as well as a negative Return on Equity. The company has a market capitalization of $821.19M and is benchmarked against industry leaders TBPH and EVO.
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
Ars Pharmaceuticals' latest earnings call revealed both early commercial success for its product Neffy and significant operational hurdles. While Neffy generated $72.2 million in U.S. net product revenue, high SG&A expenses led to an operating loss. The company plans to expand its salesforce and continue negotiations for better market access, aiming for sustained growth and improved profitability in the coming years.
Millennium-linked holders report 6.0% stake in ARS (NASDAQ: SPRY)
A Millennium-affiliated group has reported a 6.0% stake in ARS Pharmaceuticals (NASDAQ: SPRY) through a Schedule 13G/A filing. The filing indicates shared voting and dispositive power over 5,916,030 common shares, representing 6.0% of the class, by entities including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. This amendment clarifies that the securities are held by entities managed by Millennium-affiliated managers, not directly by the individuals.
ARS Pharma gains FDA clearance to remove age restriction from Neffy
ARS Pharma has received clearance from the FDA to remove the age restriction from its product Neffy. This regulatory approval will broaden the potential market and applicability of Neffy by making it available to a wider range of patients. This move is significant for ARS Pharma as it expands the commercial opportunities for their product.
FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine
The FDA has approved a labeling update for the epinephrine nasal spray neffy 1 mg, removing the minimum age requirement and allowing its use based solely on weight for pediatric patients at risk of anaphylaxis. This change broadens access to a needle-free epinephrine option, particularly for younger children who previously met weight criteria but were excluded due to age restrictions. The update also includes practical enhancements like storage recommendations and improved temperature tolerance, which can aid use in various real-world settings.
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
ARS Pharmaceuticals announced that the FDA has approved the removal of age criteria for neffy® 1 mg (epinephrine nasal spray), allowing all children and adults weighing 33 lbs or more to use it for emergency allergic reactions. Previously, pediatric patients also needed to be at least four years old. This update, along with new guidance on storage and freezing, aims to provide a needle-free, accessible option for managing anaphylaxis, particularly benefiting families with young children.
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
The article states that ARS Pharma's stock rose following the announcement that its neffy nasal spray for allergic reactions received a positive endorsement from Japan's Ministry of Health, Labour and Welfare. This endorsement recommends neffy for approval, paving the way for its potential introduction into the Japanese market as a treatment for conditions like anaphylaxis.
FDA lets younger children use needle-free neffy once they reach 33 lbs.
ARS Pharmaceuticals (SPRY) announced FDA approval to remove the age requirement for its neffy 1 mg epinephrine nasal spray, allowing its use for emergency treatment of Type 1 allergic reactions in all children and adults weighing 33 lbs or more. Previously, pediatric patients also needed to be at least four years old. This label update broadens access to a needle-free option for younger patients, and ARS Pharma will also begin including a carrying case with each prescription carton.
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
ARS Pharmaceuticals announced that the FDA has approved the removal of age criteria for its neffy® 1 mg epinephrine nasal spray, making it available for all children and adults weighing 33 lbs or more for emergency treatment of Type 1 allergic reactions. Previously, children needed to be at least four years old in addition to meeting the weight requirement. This update aims to broaden access and ease treatment for caregivers of young children who fear needle-based options, and also includes updated storage recommendations and increased flexibility for temperature excursions.
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma
The asthma market is projected to reach approximately USD 27 billion in 2024 and grow at a CAGR of 1.9% through 2034, driven by rising prevalence, advancements in therapies, and increased awareness. Key developments include new FDA approvals for generic Flovent, GSK's Exdensur for severe asthma, and AstraZeneca’s triple-combination therapy Breztri Aerosphere. The report highlights emerging therapies and major pharmaceutical companies contributing to the market's expansion across the US, EU4, UK, and Japan.
Millennium Managers Hold 5.4% of ARS Pharmaceuticals (NASDAQ: SPRY)
Millennium Management LLC and its affiliates have reported beneficial ownership of 5,391,440 shares, or 5.4%, of ARS Pharmaceuticals (NASDAQ: SPRY) common stock. This disclosure was made via a Schedule 13G filing, indicating a passive investment rather than an attempt to gain control. The filing shows shared voting and shared dispositive power among Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Time to Sell?
ARS Pharmaceuticals (NASDAQ:SPRY) shares dropped 5.7% on Monday, trading at $7.71 with reduced volume. Despite beating revenue estimates for Q4, the company remains unprofitable, with a negative net margin and ROE. Analyst coverage is mixed, with a consensus "Hold" rating and a price target of $29.33, significantly higher than the current price, while institutional investors have recently adjusted their holdings.
(SPRY) Movement Within Algorithmic Entry Frameworks
This article analyzes Ars Pharmaceuticals Inc. (NASDAQ: SPRY) through algorithmic entry frameworks, highlighting weak sentiment across all horizons and suggesting a short bias. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating weak signals across near-, mid-, and long-term horizons.
ARS Pharma secures $250M loan to accelerate Neffy rollout
ARS Pharmaceuticals has secured a $250 million loan from funds managed by Carlyle and Highbridge Capital Management. This financing will be used to support the commercial launch and rapid market penetration of Neffy, the company's nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. The loan is expected to extend ARS Pharma's cash runway through 2028.
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bamco Inc. NY significantly increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 3,071.3%, purchasing over 1.2 million additional shares. This acquisition brings their total holdings to 1,268,532 shares, representing approximately 1.28% of the company, valued at $12.75 million. Other institutional investors like Rubric Capital, Vanguard Group, Aberdeen Group, and Franklin Resources also increased their positions, contributing to institutional investors collectively owning 68.16% of the stock.
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals
Bamco Inc. NY significantly increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by over 3,000% in the third quarter of 2026, acquiring an additional 1,228,532 shares. This substantial investment, bringing Bamco's total to 1,268,532 shares, indicates growing institutional confidence in ARS Pharmaceuticals' potential, particularly its lead product candidate Neffy, for severe allergic reactions. The filing highlights the biotech firm's promising future and the importance of its innovative treatments.
